Has Japan approved frovatriptan, and when did approval happen?
Japan has an approved frovatriptan product, but the timing and specific approval date depend on the exact formulation and brand name. The provided information here does not include those approval specifics, so the approval date and the regulatory pathway (e.g., approval vs. later label changes) cannot be stated from the available context.
What frovatriptan is approved for in Japan?
Frovatriptan is a triptan-class medicine used for acute treatment of migraine attacks. In Japan, its approved indication follows how the product is labeled under Japan’s regulatory system. Exact wording (such as whether it limits use to adults, how it defines migraine, and any restrictions) requires the specific Japanese label or product entry that is not included in the provided information.
Which company markets frovatriptan in Japan?
Japan manufacturers/marketers can vary by brand and formulation. Identifying the current marketing authorization holder (and whether it is the originator or a later generic) also requires the specific Japanese product record that is not included in the provided information.
How to check the exact Japan approval status (brand, date, and label text)
To get the exact approval date, manufacturer, and the approved indication wording for the specific frovatriptan product in Japan, you typically need one of the following:
- Japan’s official drug database / package insert for the specific brand
- A regulatory-coverage database entry that lists “Japan approval” and the labeled indication
If you share the brand name or whether you mean tablet vs. another formulation, I can narrow the answer to the specific Japanese product details.